Exagen Q1 Earnings Call Highlights
Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter. The autoimmune diagnostics
MarketBeat ·